> Imagine a similar situation but where people died: Who's corporately responsible for that decision?
No idea. Thankfully, all patients stopped the drug and the toxicity went away.
I remember having a company-wide meeting where they showed us a result from the Phase I trial. It was a graph of time on the x-axis and the concentration of an important molecule in each patient's bloodstream on the y-axis. Every patient had the concentration of that molecule drop to dangerously low levels after about 5 days on the drug, and I'm thinking, "Is this a surprise to anyone here?"
No idea. Thankfully, all patients stopped the drug and the toxicity went away.
I remember having a company-wide meeting where they showed us a result from the Phase I trial. It was a graph of time on the x-axis and the concentration of an important molecule in each patient's bloodstream on the y-axis. Every patient had the concentration of that molecule drop to dangerously low levels after about 5 days on the drug, and I'm thinking, "Is this a surprise to anyone here?"